Skip Navigation LinksHome > June 2008 - Volume 30 - Issue 6 > Prolonged Survival With Continuous Infusion Topotecan: A Rep...
Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0b013e318169167b
Clinical and Laboratory Observations

Prolonged Survival With Continuous Infusion Topotecan: A Report of 2 Cases

Klopfenstein, Kathryn J. MD*; Scott, Suzanne RN, MS, CPNP; Schuller, David E. MD; Ruymann, Frederick B. MD

Collapse Box


Two patients with solid tumors were treated with 21-day continuous infusion topotecan as palliation therapy. Case 1: A 10-year-old girl was diagnosed with progressive, metastatic hepatocellular carcinoma. Twenty-one–day continuous infusion topotecan was started and she has had a partial response. Case 2: A 17-year-old girl developed a malignant fibrous histiocytoma as a second malignant neoplasm. After partial resection and failure of multiagent chemotherapy, she started continuous infusion topotecan and was disease-free for 58 months when she died of pneumonia. These cases suggest that topotecan given as 21-day continuous infusion is efficacious for palliation care.

© 2008 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us


For additional oncology content, visit LWW Oncology Journals on Facebook.